Melatonin for pre-medication in children: a systematic review

• Published in: BMC pediatrics 2022-02, Vol.22 (1), p.107-107, Article 107
• Main Authors: Mellor, Katie, Papaioannou, Diana, Thomason, Anna, Bolt, Robert, Evans, Chris, Wilson, Matthew, Deery, Chris
• Format: Article
• Language: English
• Subjects: Adult; Anesthesia; Anti-Anxiety Agents - therapeutic use; Anxiety; Anxiety - drug therapy; Care and treatment; Child; Children; Health aspects; Humans; Hypnotics and Sedatives; Melatonin; Melatonin - therapeutic use; Methods; Pediatric research; Pre-medication; Preoperative care; Risk factors; Surgery
• ISSN: 1471-2431; 1471-2431
• DOI: 10.1186/s12887-022-03149-w

Melatonin's effectiveness as an anxiolytic medication has been confirmed in adults; however, its efficacy in a paediatric population is unclear. A number of small studies have assessed its use in children as a pre-operative anxiolytic, with conflicting results. We undertook a systematic review of pre-operative melatonin use in children. Four databases (MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and Web of Science), and ' ClinicalTrials.gov ' were searched for ongoing and completed clinical trials of relevance. Citation tracking reference lists and relevant articles were also accessed. The review was unrestricted by comparator or outcomes. Eleven studies were judged eligible for inclusion. There were high levels of heterogeneity in melatonin administration (in terms of dose and timing). Variable outcomes were reported and included: anxiety; anaesthetic success; analgesia; sedation; post-operative recovery; and safety. Outcomes were not always assessed with the same measures. Evidence to support melatonin's anxiolytic properties in this setting is conflicting. Melatonin was associated with reduced sedative effects, post-operative excitement and improved emergence behaviour, compared to comparator drugs. One study reported the benefit of melatonin use on sleep disturbance at two weeks post-surgery. No adverse safety events were identified to be significantly associated with melatonin, affirming its excellent safety profile. Despite potential advantages, including improved emergence behaviour, based on current evidence we cannot confirm whether melatonin is non-inferior to current "usual care" pre-medications. Further consideration of melatonin as an anxiolytic pre-medication in paediatric surgery is needed.